Welcome to our dedicated page for Clearmind Medici news (Ticker: CMND), a resource for investors and traders seeking the latest updates and insights on Clearmind Medici stock.
Clearmind Medicine Inc. (CMND) is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel neuroplastogen-derived and psychedelic-derived therapeutics, with a lead program targeting alcohol use disorder (AUD). The Clearmind news feed on Stock Titan highlights company announcements that trace the progress of its clinical pipeline, intellectual property strategy, and exchange listing status.
News items commonly cover key milestones in Clearmind’s FDA-approved Phase I/IIa clinical trial of CMND-100, its proprietary non-hallucinogenic MEAI-based oral candidate for AUD. These updates include cohort enrollment and completion, dosing at new clinical sites such as Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center, and decisions by the independent Data and Safety Monitoring Board to allow the trial to continue following interim safety reviews.
Investors following CMND news will also see disclosures on peer-reviewed publications discussing MEAI’s pharmacological and receptor interaction profile, as well as articles that compare MEAI with other psychedelics and entactogens in the context of AUD. In addition, Clearmind regularly reports on capital markets developments, such as registered direct offerings, reverse share splits, and notifications from Nasdaq regarding compliance with minimum bid price and stockholders’ equity requirements.
This news page allows readers to track how Clearmind’s clinical-stage activities, patent portfolio expansion, and listing compliance efforts evolve over time. For anyone monitoring CMND stock or the broader field of psychedelic and neuroplastogen-based therapeutics for addiction and mental health, the Clearmind news stream provides a centralized view of the company’s publicly reported developments.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of an international patent application for a novel combination treatment using MDMA and N-Acylethanolamines. This innovative approach aims to enhance safety and efficacy in mental health and addiction treatments. The patent is part of Clearmind's collaboration with SciSparc (Nasdaq: SPRC), focusing on integrating psychedelic molecules with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized that this combination therapy addresses FDA safety concerns about MDMA by potentially reducing its dosage while maintaining therapeutic efficacy. The company has filed thirteen patents related to this collaboration in various global jurisdictions, demonstrating their commitment to developing innovative treatments for mental health disorders and addictions.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the publication of its patent application for innovative combinations of Ketamine and N-Acylethanolamines. This is a result of their ongoing collaboration with SciSparc (Nasdaq: SPRC). The companies are researching combination therapies integrating SciSparc's Palmitoylethanolamide (PEA) with Clearmind's psychedelic molecule MEAI, targeting addictions, weight loss, and mental health disorders.
To date, thirteen patents related to this collaboration have been filed globally. The goal is to develop treatments that maintain effectiveness while reducing doses and minimizing side effects. This approach could potentially address concerns associated with FDA-approved ketamine treatments, which require strict usage guidelines and close supervision due to potential side effects and abuse risks.
Clearmind Medicine Inc. (Nasdaq: CMND) has received a new patent approval from the United States Patent and Trademark Office for its MEAI-based binge behavior regulator program. The patent covers methods of regulating alcoholic beverage consumption and controlling binge behavior through the administration of amine aminoindane, including 5-methoxy-2-aminoindan (MEAI), the company's innovative psychedelic molecule.
This approval strengthens Clearmind's intellectual property portfolio, which now includes 29 granted patents across 19 patent families in key jurisdictions such as the U.S., Europe, China, and India. MEAI is a novel psychoactive molecule that reduces the desire to consume alcohol while providing a mild euphoric, alcohol-like experience. Clearmind's MEAI-based flagship treatment targets Alcohol Use Disorder (AUD) and weight loss, with potential applications in treating binge drinking.
Clearmind Medicine Inc. (Nasdaq: CMND) has announced the submission of an international patent application for generation 3.0 psychedelic compounds to treat mental disorders. This application is part of the company's ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. The patent, developed by Prof. Dmitry Tsvelikhovsky, covers new psychedelic compounds, their preparation methods, and therapeutic uses.
The PCT submission allows Clearmind to proceed with national phase applications in major jurisdictions like the US, Europe, China, and India. Dr. Adi Zuloff-Shani, CEO of Clearmind, emphasized the potential of these advanced molecules to offer improved therapeutic options for patients with mental disorders. Clearmind, a clinical-stage psychedelic pharmaceutical biotech company, focuses on developing novel psychedelic-derived therapeutics for underserved health problems, including alcohol use disorder.
Clearmind Medicine Inc. (Nasdaq: CMND) announced promising results from a study on 5-methoxy-2-aminoindane (MEAI) for combating obesity. The research, led by Prof. Joseph Tam at the Hebrew University of Jerusalem, revealed significant findings:
1. Weight loss: MEAI reduced diet-induced obesity in mice, decreasing fat mass while preserving lean mass.
2. Improved metabolism: MEAI enhanced glycemic control by reducing hyperglycemia, glucose intolerance, and hyperinsulinemia.
3. Fatty liver disease: MEAI decreased fatty liver by lowering liver triglyceride and cholesterol levels.
4. Increased energy expenditure: MEAI boosted energy expenditure and fat utilization without affecting food consumption.
5. Activity: MEAI increased activity-specific energy expenditure without overstimulation.
Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, highlighted MEAI's potential as a breakthrough in obesity treatment, citing its efficacy, unique mechanism of action, and easy administration without food consumption constraints.
Clearmind Medicine Inc. (Nasdaq: CMND) successfully participated in the Psychedelic Medicine – Israel 2024 conference in Tel Aviv. CEO Adi Zuloff-Shani presented on '5-Methoxy-2-Aminoindane (MEAI) as a Binge Behavior Regulator', highlighting its potential in treating addiction-related disorders. Researchers from The Hebrew University of Jerusalem also presented an abstract on MEAI's ability to attenuate diet-induced obesity and related metabolic complications.
The conference provided Clearmind an opportunity to showcase its innovative therapies, engage with industry leaders, and expand its network of partners. Dr. Zuloff-Shani noted that the MEAI research garnered significant interest and acceptance among event participants, reinforcing Clearmind's position in the psychedelic-derived therapeutics field.
Clearmind Medicine Inc. (Nasdaq: CMND) has partnered with JS First Sdn. Bhd to source global manufacturers and distributors for its MEAI-based alcohol substitute beverages. This strategic move follows Clearmind's recent entry into the non-alcoholic beverage market with its patented, neurologically active novel alcohol replacement drink. The beverage aims to offer the social benefits of alcohol without negative health impacts.
JS First will conduct research on manufacturing and licensing rights in foreign markets, identify manufacturing partners, and establish relationships with distributors globally. The collaboration targets markets in the U.S., Europe, Africa, and Southeast Asia. According to IWSR, the no- and low-alcohol market is valued at over $13 billion and is forecast to grow at a CAGR of +6% between 2023 and 2027.
Clearmind Medicine Inc. (Nasdaq: CMND) has received FDA approval for its Investigational New Drug (IND) application, allowing the company to proceed with a Phase I/IIa clinical trial in the United States for its proprietary MEAI-based CMND-100 oral capsule to treat alcohol use disorder (AUD). The multinational, multi-center trial will assess tolerability, safety, and pharmacokinetics in healthy volunteers and AUD subjects.
The trial will be conducted at leading universities in the US, including Yale and Johns Hopkins, as well as in Israel. The primary endpoint is to determine the tolerable dose and characterize safety and pharmacokinetics, while the secondary endpoint will evaluate preliminary efficacy in reducing drinking patterns and cravings in moderate-to-severe AUD patients.
Clearmind Medicine Inc. (Nasdaq: CMND) has submitted a new patent application to the USPTO for a novel composition combining its MEAI compound with SciSparc's PEA to treat metabolic syndrome and obesity. This application is part of ongoing collaborations with SciSparc (Nasdaq: SPRC) and Prof. Joseph Tam from the Hebrew University.
The obesity treatment market, valued at $15 billion in 2022, is expected to grow at a CAGR of 10.0% from 2023 to 2032. This growth is driven by the increasing prevalence of obesity, with the CDC reporting a 41.9% obesity rate among US adults aged 20 and over.
Clearmind has filed a total of twelve patent applications with the USPTO for various proprietary compositions, including treatments for alcohol use disorder, cocaine addiction, and obesity-related metabolic disorders.
Clearmind Medicine (Nasdaq: CMND), a clinical-stage biotech firm, will present significant research at the Psychedelic Medicine – Israel 2024 conference in Tel Aviv from July 28-30. CEO Adi Zullof-Shani, Ph.D., will discuss the potential of 5-Methoxy-2-Aminoindane (MEAI) as a regulator of binge behaviors on July 29. Additionally, researchers Prof. Joseph Tam and Dr. Saja Baraghithy will present a study on MEAI's effects on diet-induced obesity on July 30. Their findings indicate MEAI's promise in reducing obesity and improving metabolic health. The conference aims to advance psychedelic medicine through international collaboration and research dissemination.